Loading clinical trials...

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Radiofrequency Ablation of Pulmonary Malignancy

NCT00024076•Jonsson Comprehensive Cancer Center

Summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Detailed Description

OBJECTIVES: * Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies. * Determine the efficacy of this treatment, in terms of local control, in these patients. * Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients. OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours. Patients are followed at 1, 3, 6, and 12 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of a primary or secondary intrathoracic malignancy
•* Any cell type or origin
•* Involving the intrapulmonary, mediastinal, or pleural/chest wall
•* Inoperable primary or metastatic cancer to the lung
•Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
•Single or multiple lesions that are non-contiguous with vital structures or organs such as:
•Trachea
•Heart
•Aorta
•Great vessels
+5 more criteria

Locations (1)

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Key Dates

Start Date

May 1, 2000

Primary Completion Date

December 1, 2006

Last Updated

August 3, 2020

Enrollment

ACTUAL participants

Conditions

Lung CancerMalignant MesotheliomaMetastatic CancerThymoma and Thymic Carcinoma

Interventions

radiofrequency ablation

PROCEDURE

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8+2 more

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 3, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Inclusion Criteria

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Magnetic Resonance Imaging of the Lung: Oncological Applications

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations